Korea (Republic of)

Korea (Republic of)

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
2.95 (2.81 - 3.10) 2019 Modelled IHME
3.15 (3.01 - 3.30) 2018 Modelled IHME
3.24 (3.07 - 3.41) 2017 Modelled IHME
3.21 (3.06 - 3.37) 2016 Modelled IHME
3.18 (3.01 - 3.34) 2015 Modelled IHME
3.2 (3.04 - 3.36) 2014 Modelled IHME
3.25 (3.08 - 3.40) 2013 Modelled IHME
3.31 (3.15 - 3.48) 2012 Modelled IHME
3.38 (3.21 - 3.57) 2011 Modelled IHME
3.45 (3.27 - 3.65) 2010 Modelled IHME
3.49 (3.32 - 3.68) 2009 Modelled IHME
3.54 (3.38 - 3.72) 2008 Modelled IHME
3.59 (3.43 - 3.76) 2007 Modelled IHME
3.64 (3.46 - 3.82) 2006 Modelled IHME
3.69 (3.50 - 3.88) 2005 Modelled IHME
3.76 (3.58 - 3.94) 2004 Modelled IHME
3.84 (3.65 - 4.03) 2003 Modelled IHME
3.92 (3.72 - 4.13) 2002 Modelled IHME
4.01 (3.78 - 4.24) 2001 Modelled IHME
4.09 (3.84 - 4.35) 2000 Modelled IHME
4.19 (3.93 - 4.45) 1999 Modelled IHME
4.28 (4.02 - 4.55) 1998 Modelled IHME
4.38 (4.10 - 4.68) 1997 Modelled IHME
4.49 (4.20 - 4.80) 1996 Modelled IHME
4.6 (4.30 - 4.94) 1995 Modelled IHME
4.72 (4.40 - 5.06) 1994 Modelled IHME
4.84 (4.52 - 5.20) 1993 Modelled IHME
4.98 (4.63 - 5.33) 1992 Modelled IHME
5.11 (4.75 - 5.51) 1991 Modelled IHME
5.26 (4.86 - 5.69) 1990 Modelled IHME
3.15 (2.67 - 3.75) 2015 Modelled WHO
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
0.1 (0.08 - 0.13) 2019 Modelled IHME
0.11 (0.08 - 0.14) 2018 Modelled IHME
0.11 (0.08 - 0.14) 2017 Modelled IHME
0.11 (0.08 - 0.14) 2016 Modelled IHME
0.1 (0.08 - 0.14) 2015 Modelled IHME
0.11 (0.08 - 0.14) 2014 Modelled IHME
0.11 (0.09 - 0.15) 2013 Modelled IHME
0.13 (0.10 - 0.16) 2012 Modelled IHME
0.14 (0.11 - 0.18) 2011 Modelled IHME
0.15 (0.12 - 0.20) 2010 Modelled IHME
0.17 (0.13 - 0.22) 2009 Modelled IHME
0.2 (0.15 - 0.25) 2008 Modelled IHME
0.23 (0.17 - 0.29) 2007 Modelled IHME
0.26 (0.20 - 0.34) 2006 Modelled IHME
0.3 (0.23 - 0.39) 2005 Modelled IHME
0.36 (0.27 - 0.46) 2004 Modelled IHME
0.45 (0.34 - 0.57) 2003 Modelled IHME
0.53 (0.40 - 0.68) 2002 Modelled IHME
0.6 (0.45 - 0.77) 2001 Modelled IHME
0.63 (0.46 - 0.80) 2000 Modelled IHME
0.6 (0.45 - 0.77) 1999 Modelled IHME
0.55 (0.41 - 0.71) 1998 Modelled IHME
0.48 (0.36 - 0.63) 1997 Modelled IHME
0.43 (0.33 - 0.56) 1996 Modelled IHME
0.4 (0.31 - 0.53) 1995 Modelled IHME
0.42 (0.32 - 0.55) 1994 Modelled IHME
0.48 (0.37 - 0.62) 1993 Modelled IHME
0.56 (0.43 - 0.73) 1992 Modelled IHME
0.67 (0.51 - 0.88) 1991 Modelled IHME
0.8 (0.61 - 1.06) 1990 Modelled IHME
0.69 (0.49 - 0.94) 2015 Modelled WHO
0.1 2014 Survey/reported WHO WPRO, Woodring J et al, 2017
Showing out of
Show more

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
54 (46 - 63) 2019 Modelled IHME
55 (47 - 64) 2018 Modelled IHME
56 (49 - 64) 2017 Modelled IHME
57 (49 - 65) 2016 Modelled IHME
57 (50 - 65) 2015 Modelled IHME
58 (50 - 65) 2014 Modelled IHME
58 (51 - 66) 2013 Modelled IHME
59 (51 - 66) 2012 Modelled IHME
60 (52 - 67) 2011 Modelled IHME
60 (52 - 67) 2010 Modelled IHME
61 (53 - 68) 2009 Modelled IHME
61 (53 - 68) 2008 Modelled IHME
61 (54 - 68) 2007 Modelled IHME
62 (55 - 69) 2006 Modelled IHME
63 (55 - 70) 2005 Modelled IHME
63 (56 - 70) 2004 Modelled IHME
63 (56 - 70) 2003 Modelled IHME
63 (56 - 70) 2002 Modelled IHME
63 (57 - 70) 2001 Modelled IHME
63 (57 - 70) 2000 Modelled IHME
63 (57 - 70) 1999 Modelled IHME
63 (57 - 70) 1998 Modelled IHME
63 (57 - 70) 1997 Modelled IHME
63 (57 - 70) 1996 Modelled IHME
63 (57 - 69) 1995 Modelled IHME
63 (57 - 70) 1994 Modelled IHME
64 (57 - 70) 1993 Modelled IHME
64 (57 - 71) 1992 Modelled IHME
65 (58 - 72) 1991 Modelled IHME
65 (58 - 72) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of HepB birth dose

Newborns
Download
Value (%) Year Type Source
91 2018 Survey/reported WHO/UNICEF
93 2017 Survey/reported WHO/UNICEF
92 2016 Survey/reported WHO/UNICEF
98 2015 Survey/reported WHO/UNICEF
92 2014 Survey/reported WHO/UNICEF
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
98 2018 Survey/reported WHO/UNICEF
98 2017 Survey/reported WHO/UNICEF
98 2016 Survey/reported WHO/UNICEF
98 2015 Survey/reported WHO/UNICEF
99 2014 Survey/reported WHO/UNICEF
99 2013 Survey/reported WHO/UNICEF
99 2012 Survey/reported WHO/UNICEF
99 2011 Survey/reported WHO/UNICEF
94 2010 Survey/reported WHO/UNICEF
94 2009 Survey/reported WHO/UNICEF
94 2008 Survey/reported WHO/UNICEF
91 2007 Survey/reported WHO/UNICEF
99 2006 Survey/reported WHO/UNICEF
99 2005 Survey/reported WHO/UNICEF
92 2004 Survey/reported WHO/UNICEF
91 2003 Survey/reported WHO/UNICEF
92 2002 Survey/reported WHO/UNICEF
89 2001 Survey/reported WHO/UNICEF
93 2000 Survey/reported WHO/UNICEF
88 1999 Survey/reported WHO/UNICEF
82 1998 Survey/reported WHO/UNICEF
88 1997 Survey/reported WHO/UNICEF
93 1996 Survey/reported WHO/UNICEF
99 1995 Survey/reported WHO/UNICEF
Showing out of
Show more

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
0 (0 - 0) 2016 Survey/reported Harm Reduction International, 2016

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
0 2016 Survey/reported Harm Reduction International, 2016
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
Yes
Year of birth dose introduction
2001
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
No
NSP in at least one prison
No
OST in at least one prison
No

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
0.6 (0.48 - 0.74) 2019 Modelled IHME
0.59 (0.48 - 0.72) 2018 Modelled IHME
0.58 (0.47 - 0.70) 2017 Modelled IHME
0.55 (0.45 - 0.67) 2016 Modelled IHME
0.52 (0.42 - 0.64) 2015 Modelled IHME
0.49 (0.40 - 0.60) 2014 Modelled IHME
0.47 (0.39 - 0.57) 2013 Modelled IHME
0.45 (0.37 - 0.55) 2012 Modelled IHME
0.44 (0.36 - 0.53) 2011 Modelled IHME
0.43 (0.35 - 0.52) 2010 Modelled IHME
0.44 (0.37 - 0.53) 2009 Modelled IHME
0.47 (0.39 - 0.56) 2008 Modelled IHME
0.5 (0.42 - 0.60) 2007 Modelled IHME
0.53 (0.45 - 0.63) 2006 Modelled IHME
0.56 (0.46 - 0.66) 2005 Modelled IHME
0.57 (0.47 - 0.67) 2004 Modelled IHME
0.57 (0.48 - 0.68) 2003 Modelled IHME
0.58 (0.48 - 0.68) 2002 Modelled IHME
0.59 (0.49 - 0.69) 2001 Modelled IHME
0.6 (0.50 - 0.71) 2000 Modelled IHME
0.61 (0.51 - 0.72) 1999 Modelled IHME
0.64 (0.53 - 0.74) 1998 Modelled IHME
0.66 (0.55 - 0.77) 1997 Modelled IHME
0.67 (0.57 - 0.78) 1996 Modelled IHME
0.68 (0.57 - 0.79) 1995 Modelled IHME
0.67 (0.57 - 0.78) 1994 Modelled IHME
0.66 (0.56 - 0.77) 1993 Modelled IHME
0.64 (0.54 - 0.75) 1992 Modelled IHME
0.62 (0.52 - 0.72) 1991 Modelled IHME
0.59 (0.49 - 0.69) 1990 Modelled IHME
Showing out of
Show more

Prevalence of anti-HCV

National
Download
Value (%) Year Type Source
1.7 1992 Survey/reported Kim YS et al, 1992
0.8 (0.20 - 2.10) 2014 Modelled Gower et al, 2014
Showing out of
Show more
People who inject drugs (PWID)
Download
Value (%) Year Type Source
48.4 (42.80 - 54.10) 2010 Survey/reported Min JA et al, 2013

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
19 (13 - 25) 2019 Modelled IHME
19 (14 - 24) 2018 Modelled IHME
18 (14 - 24) 2017 Modelled IHME
18 (13 - 23) 2016 Modelled IHME
18 (13 - 23) 2015 Modelled IHME
17 (13 - 23) 2014 Modelled IHME
17 (13 - 22) 2013 Modelled IHME
17 (13 - 22) 2012 Modelled IHME
17 (12 - 21) 2011 Modelled IHME
16 (12 - 21) 2010 Modelled IHME
16 (12 - 21) 2009 Modelled IHME
16 (12 - 20) 2008 Modelled IHME
16 (12 - 20) 2007 Modelled IHME
15 (11 - 20) 2006 Modelled IHME
15 (11 - 19) 2005 Modelled IHME
15 (11 - 19) 2004 Modelled IHME
15 (11 - 19) 2003 Modelled IHME
15 (11 - 19) 2002 Modelled IHME
15 (11 - 19) 2001 Modelled IHME
15 (11 - 19) 2000 Modelled IHME
15 (11 - 19) 1999 Modelled IHME
15 (11 - 19) 1998 Modelled IHME
15 (11 - 19) 1997 Modelled IHME
15 (11 - 19) 1996 Modelled IHME
15 (11 - 19) 1995 Modelled IHME
15 (11 - 19) 1994 Modelled IHME
15 (11 - 19) 1993 Modelled IHME
15 (11 - 19) 1992 Modelled IHME
15 (10 - 19) 1991 Modelled IHME
14 (10 - 19) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
300 (0 - 0) 2016 Survey/reported Harm Reduction International, 2016

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
0 2016 Survey/reported Harm Reduction International, 2016
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
Yes
Year of birth dose introduction
2001
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
No
NSP in at least one prison
No
OST in at least one prison
No

Overview

HBV elimination goal
HCV elimination goal

Prevalence (national)

Modelled

HBV (HBsAg+)
2.95 (%)
2019
(2.81 - 3.1(%))
IHME
HCV (RNA/cAg+)
0.6 (%)
2019
(0.48 - 0.74(%))
IHME

Survey/surveillance

No data available
HCV (anti-HCV)
1.7 (%)
1992
Kim YS et al, 1992

Hepatitis related deaths (national)

Modelled

HBV
11,589
2019
(9,858 - 13,457)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
3,689
2019
(2,778 - 4,647)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
0.10 (%)
2014, survey/surveillance
WHO WPRO, Woodring J et al, 2017

Prevalence PWID

HCV
48.40 (%)
2010, survey/surveillance
(42.80 - 54.10(%))
Min JA et al, 2013

Birth dose vaccination coverage (national)

Survey/surveillance

HBV
91 (%)
2018
WHO/UNICEF

No. of syringes/PWID/year

Survey/surveillance

HCV
0
2016
(0 - 0)
Harm Reduction International, 2016
Eligible for HBV generic medicines
Eligible for HCV generic medicines